Oral small molecule GLP-1 receptor agonist
Loti po 200mg qd
LOTI_PO_200MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.21 (-10.56 to 0.72) | 0.81 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.38 (0.28 to 5.88) | 0.38 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 8.25 (3.87 to 17.88) | 0.09 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 12.80 (6.89 to 23.57) | 0.05 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 15.35 (7.08 to 35.96) | 0.07 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.88 (2.08 to 7.33) | 0.15 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 9.05 (4.43 to 19.40) | 0.04 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.90 (0.05 to 13.00) | 0.46 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.46 (0.01 to 17.92) | 0.56 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.16 (-11.11 to 1.49) | 0.44 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.41 (0.26 to 6.76) | 0.45 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 7.29 (2.86 to 18.04) | 0.16 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 9.54 (5.22 to 18.35) | 0.12 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 13.14 (4.97 to 37.85) | 0.14 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.85 (1.35 to 6.13) | 0.32 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 6.56 (2.59 to 17.30) | 0.10 |